{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016493", "CSN": null, "TRF": "ORD_1192856_01", "MRN": "6292279", "PhysicianId": "16468", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "889298", "clinicalId": "890703", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1192856_01", "SampleName": "US1153379.01", "Version": "0", "Sample": {"FM_Id": "ORD_1192856_01", "SampleId": "US1153379.01", "BlockId": "nan", "TRFNumber": "ORD_1192856_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2021_09_21", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "72", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99653", "MRN": "6292279", "FullName": "\u6797\u570b\u96c4", "FirstName": "Kuo_Hsiung", "LastName": "Lin", "SubmittedDiagnosis": "Small cell neuroendocrine carcinoma, Pancreas", "Gender": "Male", "DOB": "1945_05_01", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "16468", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2021_09_15", "ReceivedDate": "2021-09-29 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "10", "clinicalTrialCount": "2", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "HGF", "isVUS": "true", "variantName": "N398K"}, {"geneName": "PRDM1", "isVUS": "true", "variantName": "G391D"}, {"geneName": "RPTOR", "isVUS": "true", "variantName": "D71H"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G12D"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870). KRAS activating mutation has been reported in pancreatic small cell and large cell neuroendocrine carcinomas (NEC), at incidence of 50% of cases (Hijoka et al., 2017; 28455360, Yachida et al., 2012; 22251937) but was not observed in several studies of other types of pancreatic neuroendocrine tumors (NET) (Yachida et al., 2012; 22251937, Kubrusly et al., 2002; 12221329, Gilbert et al., 2013; 23211371, Jiao et al., 2011; 21252315, Hijoka et al., 2017; 28455360). In the context of pancreatic neuroendocrine carcinomas, KRAS mutation correlated with improved response rate to platinum_based chemotherapy (Hijoka et al., 2017; 28455360). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). While clinical responses have been reported for patients with KRAS_mutated ovarian (Monk et al., 2020; 32822286, Farley et al., 2013; 23261356, Pejovic et al., 2015; Am J Clin Exp Obstet Gynecol 2:140_143, Slosberg et al., 2018; 29765547, Han et al., 2018; 29946554), cervical small cell neuroendocrine (Lyons et al., 2014; 26075998), or uterine cancer (Slosberg et al., 2018; 29765547) treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS_altered tumors including KRAS_mutated CRC (Tsimberidou et al., 2013; ASCO Abstract e22086, Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733), pancreatic cancer (Van Laethem et al., 2017; 27975152, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), and NSCLC (Blumenschein et al., 2015; 25722381, Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS_mutated (2/2 SDs) or KRAS_amplified (1/1 SD) cancer (Lui et al., 2019; 31118140). Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS_mutated ovarian cancer (Spreafico et al., 2014; ASCO Abstract 5506, Juric et al., 2014; ASCO Abstract 9051, Banerji et al., 2014; ASCO Abstract e13559) and KRAS_mutated endometrioid adenocarcinoma (Shapiro et al., 2019; 31020608). Initial Phase 1 monotherapy trials of MEK inhibitors in patients with pancreatic cancer showed promise, with DCR (PR and/or SD) up to 37% (Bodoky et al., 2012; 21594619), response rates up to 25% (Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733), and prolonged PRs in certain patients (Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). However, subsequent clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), with refametinib and gemcitabine even showing a trend towards worse response and survival in patients with KRAS_mutant pancreatic tumors than in those with KRAS wild_type tumors (OS 6.6 months vs 18.2 months) (Van Laethem et al., 2017; 27975152). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events in patients with KRAS_mutant pancreatic cancer. Emerging preclinical studies suggest MEK inhibition downstream of KRAS_mutant pancreatic tumors leads to increased autophagy (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). Combination MEK/autophagy inhibitors may therefore be more beneficial. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine exhibited a PR (Kinsey et al., 2019; 30833748). A Phase 2 trial of paclitaxel/carboplatin with or without Reolysin in patients with metastatic pancreatic adenocarcinoma reported no improvement in PFS with addition of Reolysin, regardless of KRAS mutational status (Noonan et al., 2016; 27039845); however a Phase 2 study of Reolysin and gemcitabine in patents with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs in 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04111458", "Include": "true"}, {"nctId": "NCT03825289", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of tumor mutational burden in pancreas neuroendocrine tumors are limited (PubMed, Apr 2021). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KDM6A", "Include": "true", "Alterations": {"Alteration": {"Name": "Y362fs*2", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Y362fs*2"}}, "Interpretation": "KDM6A encodes a histone H3 lysine 27 demethylase UTX, which functions as a transcriptional regulator (van Haaften et al., 2009; 19330029). A significant number of inactivating KDM6A mutations have been found across multiple tumor types, suggesting a role as a tumor suppressor (van Haaften et al., 2009; 19330029). KDM6A mutations have been reported in 3.9% of samples analyzed, with the highest incidence in tumors of the urinary tract (31%), endometrium (7%), and salivary gland (6%) (COSMIC, 2021)(Tate et al., 2019; 30371878). KDM6A mutations or copy number alterations have also been identified in medulloblastoma (8.9%)(Robinson et al., 2012; 22722829), adenoid cystic carcinoma (6.7%) (Ho et al., 2013; 23685749), and metastatic prostate cancer (10%) (Grasso et al., 2012; 22722839). KDM6A inactivation has been found as a recurrent tumorigenic event in male T_cell acute lymphoblastic leukemia (T_ALL), and loss of KDM6A increased the sensitivity of T_ALL cells to therapies targeting histone H3 lysine 27 methylation in preclinical assays (Van der Meulen et al., 2014; 25320243). However, KDM6A overexpression has been noted in breast cancer and renal cell carcinoma, and correlated with inferior prognosis in patients with breast cancer (Wang et al., 2013; 23792809, Kim et al., 2014; 24491801, Shen et al., 2012; 23057811). There are no therapies available to address KDM6A alterations in cancer.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). One study reported higher incidence of MSI_H in high grade gastroenteropancreatic neuroendocrine cancers compared to low grade tumors (4% vs 0%)(Puccini et al., 2020; 32883742). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, MSI and associated increased mutational burden (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to anti_PD_1 and anti_PD_L1 immune checkpoint inhibitors (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92)(Gatalica et al., 2014; 25392179, Lal et al., 2015; 25949894), including the approved therapies nivolumab (alone or in combination with ipilimumab) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436), pembrolizumab (Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070), atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "L44fs*21", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "L44fs*21"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 copy number loss has been found to be common in neuroendocrine tumors, including gastrointestinal neuroendocrine tumors, and high incidences of loss of Rb protein have also been observed in poorly differentiated NECs of the gastrointestinal tract (Voortman et al., 2010; 20615970, Yachida et al., 2012; 22251937, Parwani et al., 2003; 12692194, Nassar et al., 2005; 15832081). Studies of pancreatic neuroendocrine carcinomas reported that RB expression was abnormal in 50_74% of tumors (both small and large cell NECs), and that loss of expression was correlated with mutation of the RB1 gene; in contrast, this study found that all of the well_differentiated pancreatic neuroendocrine tumors analyzed showed intact expression of Rb protein (Hijoka et al., 2017; 28455360, Yachida et al., 2012; 22251937). Loss of Rb expression in small and large cell NECs correlated with improved response rate to platinum_based chemotherapy but with inferior overall survival to unspecified chemotherapy in multivariate analysis (Hijoka et al., 2017; 28455360). Rb loss in pancreatic neurendocrine carcinoma correlated with improved response rate to platinum_based chemotherapy in one study (Tanaka et al., 2020; 32891532). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2018; 30373917, Oser et al., 2018; 30373918), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer. It should be noted that a trial of the Aurora kinase A inhibitor alisertib in advanced prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb (Condorelli et al., 2018; 29236940, Fry et al., 2004; 15542782, Dean et al., 2010; 20473330, Dean et al., 2012; 22767154, Garnett et al., 2012; 22460902, Roberts et al., 2012; 22302033, Patnaik et al., 2016; 27217383, O\u2019Leary et al., 2018; 30206110, Costa et al., 2020; 31594766, Chen et al., 2018; 29059158). Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer (Derenzini et al., 2008; 18381962, Knudsen and Knudsen, 2008; 19143056). Mutations in TP53 or RB1 are characteristic of poorly differentiated neuroendocrine carcinomas (NECs) (NCCN Neuroendocrine and Adrenal Tumors, v1.2021) (Pavel et al., 2020; 32272208, Baudin et al., 2021; 33482246, Rindi et al., 2018; 30140036, Nagtegaal et al., 2020; 31433515). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R282W", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R282W"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Although TP53 mutations are rare in pancreatic neuroendocrine tumors (NETs) (3%; 3/100 samples), aberrations in the p53 pathway commonly occur in pancreatic NETs, most often through dysregulation of its negative regulators MDM2, MDM4, and WIP1 (Hu et al., 2010; 20871795, Jiao et al., 2011; 21252315). Expression of p53 has been associated with aggressive and poorly differentiated gastroenteropancreatic NETs (O Toole et al., 2010; 20570957). A study of pancreatic NETs reported that increased p53 cytoplasmic protein expression was associated with metastasis (Weisbrod et al., 2013; 23361940). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Mutations in TP53 or RB1 are characteristic of poorly differentiated neuroendocrine carcinomas (NECs) (NCCN Neuroendocrine and Adrenal Tumors, v1.2021) (Pavel et al., 2020; 32272208, Baudin et al., 2021; 33482246, Rindi et al., 2018; 30140036, Nagtegaal et al., 2020; 31433515). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "72", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "72"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with high tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results (Li et al., 2021; AACR Abstract 2231). However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "G12D", "Title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "StudyPhase": "PHASE 1", "Target": "KRAS, SOS1, MEK", "Locations": "Frankfurt am Main (Germany), K\u00f6ln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina", "NCTID": "NCT04111458", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "28455360", "FullCitation": "Hijioka S, et al. Clin. Cancer Res. (2017) pmid: 28455360", "Include": "true"}, {"number": "25", "ReferenceId": "22251937", "FullCitation": "Yachida S, et al. Am. J. Surg. Pathol. (2012) pmid: 22251937", "Include": "true"}, {"number": "26", "ReferenceId": "12221329", "FullCitation": "Kubrusly MS, et al. JOP (2002) pmid: 12221329", "Include": "true"}, {"number": "27", "ReferenceId": "23211371", "FullCitation": "Gilbert JA, et al. Pancreas (2013) pmid: 23211371", "Include": "true"}, {"number": "28", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "29", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "30", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "31", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "32", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "33", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "34", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "35", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "36", "ReferenceId": "32822286", "FullCitation": "Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286", "Include": "true"}, {"number": "37", "ReferenceId": "23261356", "FullCitation": "Farley J, et al. Lancet Oncol. (2013) pmid: 23261356", "Include": "true"}, {"number": "38", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "39", "ReferenceId": "29946554", "FullCitation": "Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554", "Include": "true"}, {"number": "40", "ReferenceId": "26075998", "FullCitation": "Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998", "Include": "true"}, {"number": "41", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "42", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "43", "ReferenceId": "20127139", "FullCitation": "Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139", "Include": "true"}, {"number": "44", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "45", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "46", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "47", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "48", "ReferenceId": "25722381", "FullCitation": "Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381", "Include": "true"}, {"number": "49", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "50", "ReferenceId": "31118140", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140", "Include": "true"}, {"number": "51", "ReferenceId": "31020608", "FullCitation": "Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608", "Include": "true"}, {"number": "52", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "53", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "54", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "55", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "56", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "57", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "58", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "59", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "60", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "61", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "62", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "63", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "64", "ReferenceId": "19330029", "FullCitation": "van Haaften G, et al. Nat. Genet. (2009) pmid: 19330029", "Include": "true"}, {"number": "65", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "66", "ReferenceId": "22722829", "FullCitation": "Robinson G, et al. Nature (2012) pmid: 22722829", "Include": "true"}, {"number": "67", "ReferenceId": "23685749", "FullCitation": "Ho AS, et al. Nat. Genet. (2013) pmid: 23685749", "Include": "true"}, {"number": "68", "ReferenceId": "22722839", "FullCitation": "Grasso CS, et al. Nature (2012) pmid: 22722839", "Include": "true"}, {"number": "69", "ReferenceId": "25320243", "FullCitation": "Van der Meulen J, et al. Blood (2015) pmid: 25320243", "Include": "true"}, {"number": "70", "ReferenceId": "23792809", "FullCitation": "Wang L, et al. Nat Commun (2013) pmid: 23792809", "Include": "true"}, {"number": "71", "ReferenceId": "24491801", "FullCitation": "Kim JH, et al. Cancer Res. (2014) pmid: 24491801", "Include": "true"}, {"number": "72", "ReferenceId": "23057811", "FullCitation": "Shen Y, et al. BMC Cancer (2012) pmid: 23057811", "Include": "true"}, {"number": "73", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "74", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "75", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "76", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "77", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "78", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "79", "ReferenceId": "20871795", "FullCitation": "Hu W, et al. Genes Cancer (2010) pmid: 20871795", "Include": "true"}, {"number": "80", "ReferenceId": "20570957", "FullCitation": "O Toole D, et al. Endocr. Relat. Cancer (2010) pmid: 20570957", "Include": "true"}, {"number": "81", "ReferenceId": "23361940", "FullCitation": "Weisbrod AB, et al. Horm Cancer (2013) pmid: 23361940", "Include": "true"}, {"number": "82", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "83", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "84", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "85", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "86", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "87", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "88", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "89", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "90", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "91", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "92", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "93", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "94", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "95", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "96", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "97", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "98", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "99", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "100", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "101", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "102", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "103", "ReferenceId": "32272208", "FullCitation": "Pavel M, et al. Ann Oncol (2020) pmid: 32272208", "Include": "true"}, {"number": "104", "ReferenceId": "33482246", "FullCitation": "Baudin E, et al. Ann Oncol (2021) pmid: 33482246", "Include": "true"}, {"number": "105", "ReferenceId": "30140036", "FullCitation": "Rindi G, et al. Mod Pathol (2018) pmid: 30140036", "Include": "true"}, {"number": "106", "ReferenceId": "31433515", "FullCitation": "Nagtegaal ID, et al. Histopathology (2020) pmid: 31433515", "Include": "true"}, {"number": "107", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "108", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "109", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "110", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "111", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "112", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "113", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "114", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "115", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "116", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "117", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "118", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "119", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "120", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "121", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "122", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "123", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "124", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "125", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "126", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "127", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "128", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "129", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "130", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "131", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "132", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "133", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "134", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "135", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "136", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "137", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "138", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "139", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "140", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "141", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "142", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "143", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "144", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "145", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "146", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "147", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "148", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "149", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "150", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "151", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "152", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "153", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "154", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "155", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "156", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "157", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "158", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "159", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "160", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "161", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "162", "ReferenceId": "32883742", "FullCitation": "Puccini A, et al. Clin. Cancer Res. (2020) pmid: 32883742", "Include": "true"}, {"number": "163", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "164", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "165", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "166", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "167", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "168", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "169", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "170", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "171", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "172", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "173", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "174", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "175", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "176", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "177", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "178", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "179", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "180", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "181", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "182", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "183", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "184", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "185", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "186", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "187", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "188", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "189", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "190", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "191", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "192", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "193", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "194", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "195", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "196", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "197", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "198", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "199", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "200", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "201", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "202", "ReferenceId": "20615970", "FullCitation": "Voortman J, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20615970", "Include": "true"}, {"number": "203", "ReferenceId": "12692194", "FullCitation": "Parwani AV, et al. Mod. Pathol. (2003) pmid: 12692194", "Include": "true"}, {"number": "204", "ReferenceId": "15832081", "FullCitation": "Nassar H, et al. Am. J. Surg. Pathol. (2005) pmid: 15832081", "Include": "true"}, {"number": "205", "ReferenceId": "32891532", "FullCitation": "Tanaka H, et al. Pancreatology (2020) pmid: 32891532", "Include": "true"}, {"number": "206", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "207", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "208", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "209", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "210", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "211", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "212", "ReferenceId": "29236940", "FullCitation": "Condorelli R, et al. Ann. Oncol. (2018) pmid: 29236940", "Include": "true"}, {"number": "213", "ReferenceId": "15542782", "FullCitation": "Fry DW, et al. Mol. Cancer Ther. (2004) pmid: 15542782", "Include": "true"}, {"number": "214", "ReferenceId": "20473330", "FullCitation": "Dean JL, et al. Oncogene (2010) pmid: 20473330", "Include": "true"}, {"number": "215", "ReferenceId": "22767154", "FullCitation": "Dean JL, et al. Cell Cycle (2012) pmid: 22767154", "Include": "true"}, {"number": "216", "ReferenceId": "22460902", "FullCitation": "Garnett MJ, et al. Nature (2012) pmid: 22460902", "Include": "true"}, {"number": "217", "ReferenceId": "22302033", "FullCitation": "Roberts PJ, et al. J. Natl. Cancer Inst. (2012) pmid: 22302033", "Include": "true"}, {"number": "218", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "219", "ReferenceId": "30206110", "FullCitation": "O Leary B, et al. Cancer Discov (2018) pmid: 30206110", "Include": "true"}, {"number": "220", "ReferenceId": "31594766", "FullCitation": "Costa C, et al. Cancer Discov (2019) pmid: 31594766", "Include": "true"}, {"number": "221", "ReferenceId": "29059158", "FullCitation": "Chen SH, et al. Oncogene (2018) pmid: 29059158", "Include": "true"}, {"number": "222", "ReferenceId": "18381962", "FullCitation": "Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962", "Include": "true"}, {"number": "223", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "224", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "225", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "226", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "227", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "228", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "229", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "230", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "231", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "232", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "233", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "234", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "235", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "236", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "237", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "238", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "239", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "240", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "241", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "242", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_09_28 00:32:52", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "72%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas neuroendocrine carcinoma", "flowcell_analysis": "2000017768", "gender": "male", "pathology_diagnosis": "Pancreatic neuroendocrine carcinoma", "pipeline_version": "v3.7.0", "purity_assessment": "82.0", "specimen": "ORD_1192856_01*US1153379.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1192856_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1153379.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.8459", "cds_effect": "1082_1083insT", "depth": "519", "equivocal": "false", "functional_effect": "frameshift", "gene": "KDM6A", "percent_reads": "84.59", "position": "chrX:44918599", "protein_effect": "Y362fs*2", "status": "likely", "strand": "+", "transcript": "NM_021140", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.7196", "cds_effect": "131delT", "depth": "945", "equivocal": "false", "functional_effect": "frameshift", "gene": "RB1", "percent_reads": "71.96", "position": "chr13:48878178", "protein_effect": "L44fs*21", "status": "likely", "strand": "+", "transcript": "NM_000321", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.4177", "cds_effect": "1194T>A", "depth": "711", "equivocal": "false", "functional_effect": "missense", "gene": "HGF", "percent_reads": "41.77", "position": "chr7:81350138", "protein_effect": "N398K", "status": "unknown", "strand": "_", "transcript": "NM_000601", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.0071", "cds_effect": "211G>C", "depth": "840", "equivocal": "false", "functional_effect": "missense", "gene": "RPTOR", "percent_reads": "0.71", "position": "chr17:78599539", "protein_effect": "D71H", "status": "unknown", "strand": "+", "transcript": "NM_020761", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.8825", "cds_effect": "844C>T", "depth": "4478", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "88.25", "position": "chr17:7577094", "protein_effect": "R282W", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.4747", "cds_effect": "1172G>A", "depth": "2174", "equivocal": "false", "functional_effect": "missense", "gene": "PRDM1", "percent_reads": "47.47", "position": "chr6:106553207", "protein_effect": "G391D", "status": "unknown", "strand": "+", "transcript": "NM_001198", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"allele_fraction": "0.5918", "cds_effect": "35G>A", "depth": "2697", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "59.18", "position": "chr12:25398284", "protein_effect": "G12D", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.32", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "85", "status": "unknown", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"organism": "HHV_4", "reads_per_million": "119", "status": "likely", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}, {"organism": "HHV_8", "reads_per_million": "42", "status": "unknown", "dna_evidence": {"sample": "SQ_US1153379.01_1"}}]}}}}}